Trials / Terminated
TerminatedNCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- SOTIO Biotech AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Conditions
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Cutaneous Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Castration-resistant Prostate Cancer
- Ovarian Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nanrilkefusp Alfa | Subcutaneous (SC) injection. |
| DRUG | Pembrolizumab | Intravenous (IV) infusion via peripheral or central venous line. |
Timeline
- Start date
- 2022-06-21
- Primary completion
- 2024-08-31
- Completion
- 2024-11-29
- First posted
- 2022-02-25
- Last updated
- 2025-11-17
- Results posted
- 2025-11-17
Locations
54 sites across 9 countries: United States, Belgium, Czechia, France, Georgia, Hungary, Italy, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05256381. Inclusion in this directory is not an endorsement.